Nurix Therapeutics (NRIX) Other Accumulated Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Other Accumulated Expenses data on file, last reported at $1.3 million in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses rose 25.14% year-over-year to $1.3 million in Q2 2026; TTM through May 2026 was $1.3 million, a 25.14% increase from a year earlier, with the FY2025 full-year figure at $2.1 million, down 7.87% from the prior year.
• Other Accumulated Expenses for Q2 2026 stood at $1.3 million, down from $1.9 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for NRIX reached as high as $2.7 million in Q1 2025 and fell as low as $551000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.4 million across 5 years, with a median of $1.3 million in 2023.
• Across the five-year window, Other Accumulated Expenses surged 272.71% in 2022 and plunged 50.03% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.5 million in 2022, then plunged by 50.03% to $751000.0 in 2023, then soared by 202.93% to $2.3 million in 2024, then dropped by 7.87% to $2.1 million in 2025, then slumped by 37.79% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $1.3 million in Q2 2026, $1.9 million in Q1 2026, and $2.1 million in Q4 2025.